Andreas Halner
Research Subjects
Andreas Halner has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Benedikt M Kessler
Target Discovery Institute, Center for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, UK
1 shared publication- Benedikt Mathias Kessler
Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication Daniel A. Szulc
Oxford Cancer Analytics Ltd, 696, BioEscalator, Innovation Building, Old Road Campus, Roosevelt Drive, Headington, Oxford, UK
1 shared publication- Daniel Szulc
Oxford Cancer Analytics
1 shared publication - Devalben Patel
Princess Margaret Cancer Centre
1 shared publication Ella Mi
Oxford Cancer Analytics Ltd, 696, BioEscalator, Innovation Building, Old Road Campus, Roosevelt Drive, Headington, Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by Springer Nature in Research Square
Multidimensional proteomics and explainable AI feature selection identify cross-platform lung cancer molecular signature in blood plasma
Lung cancer is the leading cause of cancer mortality worldwide with 70% diagnosed late stage despite low-dose computed tomography (LDCT) screening availability. We combined data-independent acquisition mass-spectrometry (DIA-MS) and proximity extension assay (PEA) with explainable artificial intelligence (XAI)-led machine learning (ML) for plasma-based biomarker discovery. From a 490 lung cancer and 124 matched-control cohort, ML models were trained to predict lung cancer achieving an AUROC of 0.91 [95% CI: 0.88–0.93] and 0.97 [95% CI: 0.92–0.98] in DIA-MS and PEA, respectively. XAI characterised networks of model-consistent features primarily related to infection and inflammatory responses. We then introduced a DNA-aptamer proteomics method and identified a cross-platform concordance panel, with performances of 0.88 [95% CI: 0.80–0.90] and 0.88 [95% CI: 0.81–0.95] in DIA-MS and PEA, respectively. This study demonstrates that combining multi-dimensional proteomics with XAI-ML can characterise robust biomarker signatures.
- 31 October 2025
- Published by Springer Nature in Research Square
Open AccessMultidimensional proteomics and explainable AI feature selection identify cross-platform lung cancer molecular signature in blood plasma
Lung cancer is the leading cause of cancer mortality worldwide with 70% diagnosed late stage despite low-dose computed tomography (LDCT) screening availability. We combined data-independent acquisition mass-spectrometry (DIA-MS) and proximity extension assay (PEA) with explainable artificial intelligence (XAI)-led machine learning (ML) for plasma-based biomarker discovery. From a 490 lung cancer and 124 matched-control cohort, ML models were trained to predict lung cancer achieving an AUROC of 0.91 [95% CI: 0.88–0.93] and 0.97 [95% CI: 0.92–0.98] in DIA-MS and PEA, respectively. XAI characterised networks of model-consistent features primarily related to infection and inflammatory responses. We then introduced a DNA-aptamer proteomics method and identified a cross-platform concordance panel, with performances of 0.88 [95% CI: 0.80–0.90] and 0.88 [95% CI: 0.81–0.95] in DIA-MS and PEA, respectively. This study demonstrates that combining multi-dimensional proteomics with XAI-ML can characterise robust biomarker signatures.